DM和某些cancer有關，insulin和某些cancer有關，metformin較OK
Diabetes and Cancer Groups Issue Consensus Report
Experts from the American Diabetes Association and the American Cancer Society have published a consensus report on the association between diabetes and some types of cancer in CA: A Cancer Journal for Clinicians.
Their observations and recommendations include the following:
Among the cancers associated with diabetes, the risk is highest for liver, pancreatic and endometrial cancers (roughly 2-fold or more) and lower for colorectal, breast, and bladder cancers (about 1.2- to 1.5-fold).
Possible mechanisms to explain the association include hyperinsulinemia, hyperglycemia, and inflammation. Shared risk factors (e.g., obesity, aging, diet) may also play a role.
Early studies indicate that metformin may be associated with a lower cancer risk while exogenous insulin may be associated with a higher risk. (More data are needed to determine whether insulin glargine poses greater risk than other insulins.)
Cancer risk should not determine diabetes treatment in an average patient, but it may be a consideration in a higher-risk patient (e.g., one at risk for recurrence).
CA: A Cancer Journal for Clinicians article (Free)
Experts from the American Diabetes Association and the American Cancer Society have published a consensus report on the association between diabetes and some types of cancer in CA: A Cancer Journal for Clinicians.
Their observations and recommendations include the following:
Among the cancers associated with diabetes, the risk is highest for liver, pancreatic and endometrial cancers (roughly 2-fold or more) and lower for colorectal, breast, and bladder cancers (about 1.2- to 1.5-fold).
Possible mechanisms to explain the association include hyperinsulinemia, hyperglycemia, and inflammation. Shared risk factors (e.g., obesity, aging, diet) may also play a role.
Early studies indicate that metformin may be associated with a lower cancer risk while exogenous insulin may be associated with a higher risk. (More data are needed to determine whether insulin glargine poses greater risk than other insulins.)
Cancer risk should not determine diabetes treatment in an average patient, but it may be a consideration in a higher-risk patient (e.g., one at risk for recurrence).
CA: A Cancer Journal for Clinicians article (Free)
留言
張貼留言